Etravirine Patent Expiration
Etravirine is used for treating HIV-1 infection in patients who are treatment-experienced and have evidence of viral replication and resistance to certain antiretroviral drugs. It was first introduced by Janssen Research And Development Llc
Etravirine Patents
Given below is the list of patents protecting Etravirine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Intelence |
US7037917 (Pediatric) | HIV replication inhibiting pyrimidines |
Jun 13, 2021
(Expired) | Janssen R And D |
| Intelence | US7037917 | HIV replication inhibiting pyrimidines |
Dec 13, 2020
(Expired) | Janssen R And D |
| Intelence |
US6878717 (Pediatric) | HIV replication inhibiting pyrimidines |
May 05, 2020
(Expired) | Janssen R And D |
| Intelence |
US8003789 (Pediatric) | HIV replication inhibiting pyrimidines |
May 01, 2020
(Expired) | Janssen R And D |
| Intelence | US6878717 | HIV replication inhibiting pyrimidines |
Nov 05, 2019
(Expired) | Janssen R And D |
| Intelence | US8003789 | HIV replication inhibiting pyrimidines |
Nov 01, 2019
(Expired) | Janssen R And D |
| Intelence |
US7887845 (Pediatric) | Antiviral compositions |
Sep 25, 2019
(Expired) | Janssen R And D |
| Intelence | US7887845 | Antiviral compositions |
Mar 25, 2019
(Expired) | Janssen R And D |
Etravirine's Family Patents
Explore Our Curated Drug Screens
Etravirine Generic API Manufacturers
Several generic applications have been filed for Etravirine. The first generic version for Etravirine was by Amneal Eu Ltd and was approved on Jun 14, 2021. And the latest generic version is by Carnegie Pharmaceuticals Llc and was approved on Apr 13, 2022.
Given below is the list of companies who have filed for Etravirine generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL
Amneal Eu Ltd has filed for 3 different strengths of generic version for Etravirine. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Discontinued | ORAL | N/A | Jun 14, 2021 |
| 100MG | tablet | Prescription | ORAL | AB | Jun 14, 2021 |
| 200MG | tablet | Prescription | ORAL | AB | Jun 14, 2021 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
2. CARNEGIE
Carnegie Pharmaceuticals Llc has filed for 2 different strengths of generic version for Etravirine. Given below are the details of the strengths of this generic introduced by Carnegie.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Prescription | ORAL | AB | Apr 13, 2022 |
| 200MG | tablet | Prescription | ORAL | AB | Apr 13, 2022 |
Manufacturing Plant Locations New
Carnegie's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Carnegie as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||